Phase 1 Rheumatoid Arthritis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
For people with early rheumatoid arthritis (RA):
- People who are able to give written consent to participate
- People aged 18 or older
- People who have been diagnosed with rheumatoid arthritis according to 2010 ACR criteria, with a disease activity score (DAS28-CRP) above 3.5, indicating moderate-to-high disease activity
- People who have had rheumatoid arthritis for 1 year or less
- People whose RA has not responded well enough to methotrexate treatment (still showing disease activity after 4 months), OR people who have had a flare-up while on methotrexate AND who are starting an anti-TNF therapy (a type of biologic medication)
- People who have confirmed active joint inflammation in one or both hands, shown by ultrasound
For people with established rheumatoid arthritis (RA):
- People who are able to give written consent to participate
- People aged 18 or older
- People who have been diagnosed with rheumatoid arthritis according to 2010 ACR criteria, with a disease activity score (DAS28-CRP) above 3.5
- People who have had rheumatoid arthritis for at least 10 years
- People who have confirmed active joint inflammation in one or both hands, shown by ultrasound
- People who have been on a stable dose of a DMARD medication (such as methotrexate, leflunomide, azulfidine, or hydroxychloroquine), a JAK inhibitor, or a biologic medication for at least 8 weeks
Who may not be able to join:
- People who have other active systemic or inflammatory conditions besides rheumatoid arthritis, including chronic infections such as hepatitis B, hepatitis C, or HIV
- People who have a known allergy or sensitivity to iodine, due to a small amount of iodine present in a substance used in the study (Indocyanine Green)
- People who are pregnant
- People who are unable to have blood drawn due to poor vein access
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Christopher Ritchlin, MD, MPH, University of Rochester
Phone: 585-275-1634
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Clearance
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.